AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.030

-0.001-3.23%

Volume:8.33M

Turnover:258.50K

Market Cap:93.98M

PE:-8.08

High:0.033

Open:0.031

Low:0.029

Close:0.031

Loading ...

Overview Company News Filings

ASX Market Close: Index claws back losses to close flat | December 9, 2024

The Market Herald

Actinogen Medical Doses First Participant in Alzheimer's Disease Trial in US; Shares Rise Nearly 7%

MT Newswires Live

<em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em>

The Market Herald

Actinogen receives $9M R&D tax rebate to fund Alzheimer’s trial

The Market Herald

Corrected-Actinogen Medical Ltd-a$3.0 Million Share Purchase Plan Closes 1.3X Oversubscribed (Corrects Currency to a$)

THOMSON REUTERS

BRIEF-Actinogen Medical Says A$3.0 Mln Share Purchase Plan Closes

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The Market Herald

Actinogen Medical Ltd-Update - Application for Quotation of Securities - Acw

THOMSON REUTERS

Actinogen Medical Ltd-Share Purchase Plan & Options Prospectus

THOMSON REUTERS

Actinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%

MT Newswires Live

BUZZ-Australia's Actinogen Medical falls on discounted placement

Why Actinogen Medical, Flight Centre, JB Hi-Fi, and NextDC shares are falling today

BRIEF-Actinogen Medical Announces Launch Of A$3.0 Mln Share Purchase Plan

Actinogen Medical Ltd - a$11.1M Capital Raising to Accelerate Alzheimers Trial

THOMSON REUTERS

Actinogen Medical - Capital Raising Is at Issue Price of a$0.03 per New Share

THOMSON REUTERS

Actinogen Medical Ltd - Launch of a$3.0 Mln Share Purchase Plan

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACW.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACW.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.03,"timestamp":1741233415907,"preClose":0.031,"halted":0,"volume":8334379,"delay":0,"changeRate":-0.032258,"change":-0.001,"floatShares":2369911063,"shares":3132813906,"eps":-0.003712,"lyrEps":-0.005999,"pbRate":3.92,"amount":258504,"amplitude":0.129032,"volumeRatio":0.878252,"dividePrice":0,"prevYearClose":0.025,"fiveDayClose":0.04,"twentyDayClose":0.033},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2369911063,"roa":"-31.46%","roe":"-53.73%","lyrEps":-0.005999,"volumeRatio":0.878252,"shares":3132813906,"dividePrice":0,"high":0.033,"amplitude":0.129032,"preClose":0.031,"low":0.029,"week52Low":0.021,"pbRate":"3.92","psRate":"10.42","week52High":0.099,"institutionHeld":0,"latestPrice":0.03,"committee":-0.411672,"eps":-0.003712,"divideRate":0,"volume":8334379,"delay":0,"ttmEps":-0.003712,"open":0.031,"prevYearClose":0.025,"prevWeekClose":0.04,"prevMonthClose":0.04,"prevQuarterClose":0.025,"fiveDayClose":0.04,"twentyDayClose":0.033,"sixtyDayClose":0.031},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490004718","title":"ASX Market Close: Index claws back losses to close flat | December 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004718","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490004718?lang=en_us&edition=fundamental","pubTime":"2024-12-09 13:50","pubTimestamp":1733723400,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.03% at 8,423 points.Gold rose after China’s central bank added bullion to its reserves in November, resuming a key pillar of support for the precious metal. Bullion climbed by 0.5% to US$2,640.Energy was the worst performing sector, down 1%, followed by Materials and Information Technology, both down 0.4%. Discretionary finished the best performer, up 0.65%, followed by Telecommunication, up 0.36%, and Health Care, up 0.3%.Southern Cross Goldclosed up 6.77% on news of a discovery at the Apollo prospect within its 100%-owned Sunday Creek Gold-Antimony Project in Victoria. The exceptional results confirm the potential for Sunday Creek to rank among the world’s leading gold-antimony discoveries.Vection Technologies  closed up 15.00% after inking new contracts worth $500,000 with global brands Natuzzi and Nestlé. The agreements underscore Vection’s evolving role in enhancing business operations through its AI and XR ecosystem.Actinogen Medical  kicked off its Phase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-claws-back-losses-to-close-flat-december-9-2024-2024-12-09/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7016","360.AU","BK7067","BK7508","BK7095","WDS.AU","SGA.AU","VR1.AU","BK7104","SXG.AU","BK7142","ACW.AU"],"gpt_icon":0},{"id":"2490794668","title":"Actinogen Medical Doses First Participant in Alzheimer's Disease Trial in US; Shares Rise Nearly 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490794668","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490794668?lang=en_us&edition=fundamental","pubTime":"2024-12-09 12:10","pubTimestamp":1733717416,"startTime":"0","endTime":"0","summary":"Actinogen Medical (ASX:ACW) dosed the first participant of a phase 2b/3 trial in the US of XanaMIA in patients with biomarker-positive mild to moderate Alzheimer's disease, according to a Monday filin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","BK4125","LU1043141123.HKD","AUD","LU0345774631.USD","LU0426412945.USD","ACW.AU","LU2238339852.HKD","BK7067","BK7508","LU0426417589.USD"],"gpt_icon":0},{"id":"2486792724","title":"<em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em>","url":"https://stock-news.laohu8.com/highlight/detail?id=2486792724","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486792724?lang=en_us&edition=fundamental","pubTime":"2024-11-25 00:00","pubTimestamp":1732464000,"startTime":"0","endTime":"0","summary":"For years, people dreamed that science would one day create a pill to cure all ills.Today, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by addressing debilitating conditions like depression and Alzheimer’s.This is the promise of Xanamem, a breakthrough from Actinogen Medical  that could improve the lives of millions in Australia and around the world.Depression and Alzheimer’s are among the most widespread mental health challenges in Australia, affecting countless individuals and families. Decades of research has highlighted a link between these conditions and cortisol—a hormone related to stress.Actinogen’s Xanamem is the first medication that can control brain tissue cortisol without affecting normal levels of cortisol needed in the rest of the body.Xanamem provides a novel approach to managing depression, known as the “black dog,” and for slowing Alzheimer’s progression.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/this-biotech-stock-raised-11m-in-a-risk-off-environment-its-alzheimers-drug-could-change-the-game-2024-11-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7508","XJO.AU","XKO.AU","ACW.AU","XAO.AU"],"gpt_icon":0},{"id":"2482719483","title":"Actinogen receives $9M R&D tax rebate to fund Alzheimer’s trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482719483","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482719483?lang=en_us&edition=fundamental","pubTime":"2024-11-12 10:41","pubTimestamp":1731379260,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd  has received a $9 million R&D  tax incentive rebate for the 2024 fiscal year, based on clinical tests of its lead compound Xanamem – a prospective therapy for Alzheimer’s Disease and Depression.The R& D rebate – which for Actinogen amounted to $9,034,351 – is a Federal government program which provides companies with cash refunds for eligible research and development expenditure.Together with funds on hand, the rebate means Actinogen is financially supported up to mid-2026, facilitating its full enrolment of 220 participants in its Alzheimer’s phase 2b/3 clinical trial.Xanamem is the key initiative which Actinogen is focusing on as a novel therapy for neurological neuropsychiatric diseases associated with dysregulated brain cortisol, and it controls the level of this chemical through the inhibition of the cortisol synthesis enzyme, 11β-HSD1, without affecting production of cortisol by the adrenal glands.The drug is designed to enter the brain after it is absorbed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/actinogen-receives-9m-rd-tax-rebate-to-fund-alzheimers-trial-2024-11-12/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2474738679","title":"Corrected-Actinogen Medical Ltd-a$3.0 Million Share Purchase Plan Closes 1.3X Oversubscribed (Corrects Currency to a$)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474738679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474738679?lang=en_us&edition=fundamental","pubTime":"2024-10-10 08:43","pubTimestamp":1728521006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nL8N3LM00Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2474389267","title":"BRIEF-Actinogen Medical Says A$3.0 Mln Share Purchase Plan Closes","url":"https://stock-news.laohu8.com/highlight/detail?id=2474389267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474389267?lang=en_us&edition=fundamental","pubTime":"2024-10-10 08:43","pubTimestamp":1728521006,"startTime":"0","endTime":"0","summary":"Oct 10 (Reuters) - Actinogen Medical Ltd   :   * A$3.0 MILLION SHARE PURCHASE PLAN CLOSES 1.3X OVERSUBSCRIBEDFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2469457307","title":"Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2469457307","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469457307?lang=en_us&edition=fundamental","pubTime":"2024-09-24 10:22","pubTimestamp":1727144520,"startTime":"0","endTime":"0","summary":"Actinogen Medical  is developing a promising oral treatment for Alzheimer’s and depression and is accelerating clinical trials with new capital.CEO Steven Gourlay, joins The Market Onlineto discuss the company’s development.Join the discussion:See whatHotCopper users are saying about Actinogen Medical Ltd and be part of the conversations that move the markets.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/actinogen-medical-ramps-up-alzheimers-treatment-trials-targeting-fast-track-global-approvals-2024-09-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2469032104","title":"Actinogen Medical Ltd-Update - Application for Quotation of Securities - Acw","url":"https://stock-news.laohu8.com/highlight/detail?id=2469032104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469032104?lang=en_us&edition=fundamental","pubTime":"2024-09-24 09:38","pubTimestamp":1727141896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nTUE5Q2LXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2468699212","title":"Actinogen Medical Ltd-Share Purchase Plan & Options Prospectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2468699212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468699212?lang=en_us&edition=fundamental","pubTime":"2024-09-20 15:06","pubTimestamp":1726816008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240920:nTUE1N3P1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2468322062","title":"Actinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468322062","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468322062?lang=en_us&edition=fundamental","pubTime":"2024-09-18 14:06","pubTimestamp":1726639615,"startTime":"0","endTime":"0","summary":"Actinogen Medical  completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the Australian bourse.The placement comprised roughly 270 million new shares issued at AU$0.03 each, with three options granted for every four shares. The options are exercisable at AU$0.05 and will expire on Sept. 30, 2027.Chief Executive Officer Steven Gourlay subscribed for AU$1 million in the placement, while other directors subscribed for a total of AU$130,000, subject to shareholder approval.Meanwhile, the share purchase plan offers a maximum of 100 million shares and 75 million new options on the same terms as the placement, the filing stated.The biotechnology company's shares were down nearly 9% in recent Wednesday. trade.Price : $0.03, Change: $-0.0030, Percent Change: -8.57%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","AUD","ACW.AU","BK7067","BK4125"],"gpt_icon":0},{"id":"2468349919","title":"BUZZ-Australia's Actinogen Medical falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2468349919","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468349919?lang=en_us&edition=fundamental","pubTime":"2024-09-18 10:03","pubTimestamp":1726625035,"startTime":"0","endTime":"0","summary":"** Shares of Actinogen Medical Ltd    fall as much as 14.3% to A$0.030, their lowest since Aug 26     ** The biotechnology firm raises A$11.1 mln  via share placement and share purchase plan   ** The placement price of A$0.03 per share represents a 14.3% discount to ACW's last closing price   ** Co says funds from capital raise will be used to  accelerate enrolment and trial of patients with Alzheimer's disease   ** ACW stock up 36.4% YTD    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XKO.AU","BK7067","BK7508","XJO.AU","XAO.AU","ACW.AU"],"gpt_icon":0},{"id":"2468349313","title":"Why Actinogen Medical, Flight Centre, JB Hi-Fi, and NextDC shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2468349313","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468349313?lang=en_us&edition=fundamental","pubTime":"2024-09-18 10:01","pubTimestamp":1726624861,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a subdued session on Wednesday. At the time of writing, the benchmark index is down slightly to 8,140 points. Four ASX shares that are falling more than most t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/09/18/why-actinogen-medical-flight-centre-jb-hi-fi-and-nextdc-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","NXT.AU","ACW.AU","BK7043","BK7067","FLT.AU","BK7001","JBH.AU","BK7070","BK7508","BK7503"],"gpt_icon":0},{"id":"2468453433","title":"BRIEF-Actinogen Medical Announces Launch Of A$3.0 Mln Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2468453433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468453433?lang=en_us&edition=fundamental","pubTime":"2024-09-18 09:27","pubTimestamp":1726622845,"startTime":"0","endTime":"0","summary":"Sept 18 (Reuters) - Actinogen Medical Ltd   :   * LAUNCH OF A$3.0 MILLION SHARE PURCHASE PLAN   * A$11.1M CAPITAL RAISING TO ACCELERATE ALZHEIMERS TRIAL   * CAPITAL RAISING IS AT ISSUE PRICE OF A$0.03 PER NEW SHAREFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2468310247","title":"Actinogen Medical Ltd - a$11.1M Capital Raising to Accelerate Alzheimers Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2468310247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468310247?lang=en_us&edition=fundamental","pubTime":"2024-09-18 08:46","pubTimestamp":1726620365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nFWN3KZ0W9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"gpt_icon":0},{"id":"2468310244","title":"Actinogen Medical - Capital Raising Is at Issue Price of a$0.03 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2468310244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468310244?lang=en_us&edition=fundamental","pubTime":"2024-09-18 08:46","pubTimestamp":1726620365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nFWN3KZ0W9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2468102423","title":"Actinogen Medical Ltd - Launch of a$3.0 Mln Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2468102423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468102423?lang=en_us&edition=fundamental","pubTime":"2024-09-18 08:46","pubTimestamp":1726620365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nFWN3KZ0W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":2,"totalSize":34}]}}